NCT07387926 2026-02-04
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
Clinical Trials
11 trialsNCT07035379 2025-08-22
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1/2 Not yet recruiting
NCT06594640 2025-05-14
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Recruiting
NCT04914741 2024-08-12
COALITION
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT01897571 2024-03-26
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
Phase 1/2 Completed
NCT03571308 2023-09-28
ACCEPT
University Hospital Southampton NHS Foundation Trust
Phase 1/2 Completed
NCT05320380 2023-09-01
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Children's Oncology Group
Phase 1/2 Withdrawn
NCT01992653 2023-03-14
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Genentech, Inc.
Phase 1/2 Completed
NCT01198665 2015-03-03
RADCHOP
Samsung Medical Center
Phase 1/2 Completed
NCT00032149 2013-09-20
Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00379574 2013-03-15
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Asan Medical Center
Phase 1/2 Completed